Skip to main content
. 2022 Dec 1;132(23):e162282. doi: 10.1172/JCI162282

Figure 1. SARS-CoV-2 nucleocapsid–specific antibody after SARS-CoV-2 infection in a cohort of patients admitted to Northwestern University Hospital.

Figure 1

(A) Human pre-2019 plasma samples from healthy individuals were used as a control. Data shown are from an ongoing study, in which participants were infected on different dates, hence the heterogeneity in the nucleocapsid-specific antibody responses. SARS-CoV-2 infection was confirmed by RT-PCR. Antibody responses were evaluated by ELISA. (B) Summary of SARS-CoV-2 nucleocapsid–specific antibodies in sera. (C) Summary of influenza HA–specific antibodies in sera (used as an irrelevant antigen control). Dashed lines represent the LOD. Significance in B and C was determine by Mann-Whitney U test. Error bars represent the SEM.